Clinical Trial Update: ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ASKC202 in combination with Limertinib versus platinum-based chemotherapy for locally advanced or metastatic non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASKC202
• Limertinib (Limertinib)

Snippet

Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Conditions: Locally Advanced or Metastatic NSCLC | Phase 3 | Status: NOT_YET_RECRUITING